An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Verona Pharma plc (Nasdaq: VRNA) will report its first quarter 2024 financial results on May 9, 2024, and hold an investment community conference call to discuss the results. The Company encourages participation through dial-in or live webcast, with further details available on their website. Contact information for investor and media inquiries is also provided in the press release.
Verona Pharma plc (Nasdaq: VRNA) rilascerà i risultati finanziari del primo trimestre del 2024 il 9 maggio 2024 e terrà una conference call con la comunità degli investitori per discutere i risultati. L'azienda invita a partecipare tramite collegamento telefonico o trasmissione web in diretta, ulteriori dettagli sono disponibili sul loro sito web. Sono inoltre fornite informazioni di contatto per gli investitori e le richieste dei media nel comunicato stampa.
Verona Pharma plc (Nasdaq: VRNA) informará sobre sus resultados financieros del primer trimestre de 2024 el 9 de mayo de 2024, y realizará una llamada de conferencia con la comunidad de inversores para discutir los resultados. La compañía recomienda la participación a través de llamada telefónica o webcast en vivo, con más detalles disponibles en su sitio web. También se proporciona información de contacto para consultas de inversores y medios en el comunicado de prensa.
Verona Pharma plc (나스닥: VRNA)는 2024년 1/4분기 재무 결과를 2024년 5월 9일에 발표하고, 결과에 대해 투자자 커뮤니티와 설명할 컨퍼런스 콜을 진행할 예정입니다. 회사는 전화 참여 또는 생방송 웹캐스트를 통한 참여를 권장하며, 자세한 내용은 웹사이트에서 확인할 수 있습니다. 투자자 및 언론 문의를 위한 연락처 정보도 보도 자료에 제공되어 있습니다.
Verona Pharma plc (Nasdaq : VRNA) publiera ses résultats financiers pour le premier trimestre 2024 le 9 mai 2024 et organisera une conférence téléphonique avec la communauté des investisseurs pour discuter des résultats. La société encourage la participation par téléphone ou par webcast en direct, avec plus de détails disponibles sur leur site web. Les informations de contact pour les investisseurs et les demandes des médias sont également fournies dans le communiqué de presse.
Verona Pharma plc (Nasdaq: VRNA) wird am 9. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben und eine Telefonkonferenz mit der Investorengemeinschaft abhalten, um die Ergebnisse zu diskutieren. Das Unternehmen ermutigt zur Teilnahme per Telefon oder Live-Webcast, weitere Details sind auf ihrer Website verfügbar. Kontaktinformationen für Investoren- und Medienanfragen sind ebenfalls in der Pressemitteilung enthalten.
Positive
None.
Negative
None.
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
To participate, please dial one of the following numbers and ask to join the Verona Pharma call:
+1-833-816-1396 for callers in the United States
+1-412-317-0489 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days.
For further information please contact:
Verona Pharma plc
US Tel: +1-833-417-0262
UK Tel: +44 (0)203 283 4200
Victoria Stewart, Senior Director of Investor Relations and Communications
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. In the third quarter of 2023, the US Food and Drug Administration accepted for review the Company’s NDA for ensifentrine for the maintenance treatment of patients with COPD and assigned a PDUFA target action date of June 26, 2024. If approved, ensifentrine has the potential to become the first non-steroidal therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one molecule. The Company has evaluated nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine substantially reduced the rate and risk of COPD exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. Two additional formulations of ensifentrine have been evaluated in Phase 2 trials for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”); and a fixed-dose combination formulation with ensifentrine and glycopyrrolate, a LAMA, is currently under development, also for the treatment of COPD. Ensifentrine also has potential applications in cystic fibrosis, non-cystic fibrosis bronchiectasis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com
FAQ
When will Verona Pharma report its first quarter 2024 financial results?
Verona Pharma will report its first quarter 2024 financial results on May 9, 2024.
What time will the investment community conference call to discuss the financial results take place?
The investment community conference call to discuss the financial results will be at 9:00 a.m. EDT / 2:00 p.m. BST on May 9, 2024.
How can I participate in the Verona Pharma conference call?
To participate in the Verona Pharma conference call, dial either +1-833-816-1396 for US callers or +1-412-317-0489 for international callers.
Where can I find the live webcast of the event?
The live webcast of the event will be available on the Events and Presentations link on the Investors page of Verona Pharma's website.
How long will the audio replay of the conference call be available?
The audio replay of the conference call will be available for 90 days.
verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin
